Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance

BACKGROUND: Eculizumab has been available for the treatment of atypical hemolytic–uremic syndrome (aHUS) in Japan since 2013. To assess safety and effectiveness of eculizumab in adult aHUS patients in the real-life setting, we performed interim analysis of a post-marketing surveillance mandated by J...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Hideki, Miyakawa, Yoshitaka, Hidaka, Yoshihiko, Inoue, Norimitsu, Ito, Shuichi, Kagami, Shoji, Kaname, Shinya, Matsumoto, Masanori, Mizuno, Masashi, Matsuda, Takahisa, Shimono, Akihiko, Maruyama, Shoichi, Fujimura, Yoshihiro, Nangaku, Masaomi, Okada, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344388/
https://www.ncbi.nlm.nih.gov/pubmed/29959568
http://dx.doi.org/10.1007/s10157-018-1609-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344388/
https://www.ncbi.nlm.nih.gov/pubmed/29959568
http://dx.doi.org/10.1007/s10157-018-1609-8

Ejemplares similares